D'Este Francesca, Della Pietra Emilia, Badillo Pazmay Gretta Veronica, Xodo Luigi E, Rapozzi Valentina
Department of Medicine, University of Udine, P.le Kolbe 4, 33100 Udine, Italy.
Department of Medicine, University of Udine, P.le Kolbe 4, 33100 Udine, Italy.
Biochem Pharmacol. 2020 Dec;182:114205. doi: 10.1016/j.bcp.2020.114205. Epub 2020 Aug 20.
A continuous state of oxidative stress during inflammation contributes to the development of 25% of human cancers. Epithelial and inflammatory cells release reactive oxygen species (ROS) and reactive nitrogen species (RNS) that can damage DNA. ROS/RNS have biological implications in both chemoresistance and tumor recurrence. As several clinically employed anticancer drugs can generate ROS/RNS, we have addressed herein how inducible nitric oxide synthase and nitric oxide (iNOS/NO) affect the molecular pathways implicated in the tumor response to oxidative stress. To mimic the oxidative stress associated with chemotherapy, we used a photosensitizer (pheophorbide a) that can generate ROS/RNS in a controlled manner. We investigated how iNOS/NO modulates the tumor response to oxidative stress by involving the NF-κB and Nrf2 molecular pathways. We found that low levels of iNOS induce the development of a more aggressive tumor population, leading to survival, recurrence and resistance. By contrast, high levels of iNOS/NO sensitize tumor cells to oxidative treatment, causing cell growth arrest. Our analysis showed that NF-κB and Nrf2, which are activated in response to oxidative stress, communicate with each other through RKIP. For this critical role, RKIP could be an interesting target for anticancer drugs. Our study provides insight into the complex signaling response of cancer cells to oxidative treatments as well as new possibilities for the rational design of new therapeutic strategies.
炎症期间持续的氧化应激状态导致25%的人类癌症发生。上皮细胞和炎症细胞会释放可损伤DNA的活性氧(ROS)和活性氮(RNS)。ROS/RNS在化疗耐药性和肿瘤复发方面都具有生物学意义。由于几种临床应用的抗癌药物可产生ROS/RNS,我们在此探讨了诱导型一氧化氮合酶和一氧化氮(iNOS/NO)如何影响与肿瘤对氧化应激反应相关的分子途径。为模拟与化疗相关的氧化应激,我们使用了一种能以可控方式产生活性氧/活性氮的光敏剂(脱镁叶绿酸a)。我们研究了iNOS/NO如何通过涉及核因子κB(NF-κB)和核因子E2相关因子2(Nrf2)分子途径来调节肿瘤对氧化应激的反应。我们发现低水平的iNOS会诱导更具侵袭性的肿瘤群体的发展,导致存活、复发和耐药。相比之下,高水平的iNOS/NO会使肿瘤细胞对氧化治疗敏感,导致细胞生长停滞。我们的分析表明,在氧化应激反应中被激活的NF-κB和Nrf2通过 Raf激酶抑制蛋白(RKIP)相互沟通。鉴于这一关键作用,RKIP可能成为抗癌药物的一个有吸引力的靶点。我们的研究深入了解了癌细胞对氧化治疗的复杂信号反应,也为合理设计新的治疗策略提供了新的可能性。